Peter Chatfield
Impact in
- Oncology top 10%
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
-
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
Papers in
-
- Ovarian cancer diagnosis and treatment 2
-
- Prostate Cancer Treatment and Research 3
- Prostate Cancer Diagnosis and Treatment 2
- Co-authors
- Dow‐Mu Koh (2 shared papers)John Nicholas Staffurth (2 shared papers)Emma Hall (2 shared papers)Anwar R. Padhani (2 shared papers)Holly Tovey (4 shared papers)Nina Tunariu (4 shared papers)Sophie L. Perry (4 shared papers)Chris C. Parker (2 shared papers)
- Journals
- The Lancet Oncology (1 paper)Therapeutic Advances in Medical Oncology (1 paper)Annals of Oncology (1 paper)Clinical Genitourinary Cancer (1 paper)JNCI Cancer Spectrum (1 paper)
- Partner nations
- United KingdomNew ZealandBrazil
In The Last Decade
Peter Chatfield
5 papers receiving 559 citations
Peter Chatfield's Hit Papers
Peers
Comparison fields: 5 of 34
- Oncology 281
- Pulmonary and Respiratory Medicine 243
- Cancer Research 54
- Genetics 89
- Radiology, Nuclear Medicine and Imaging 19
Countries citing papers authored by Peter Chatfield
This map shows the geographic impact of Peter Chatfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Chatfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Chatfield more than expected).
Fields of papers citing papers by Peter Chatfield
This network shows the impact of papers produced by Peter Chatfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Chatfield. The network helps show where Peter Chatfield may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Chatfield, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial Hit paper breakdown → | 2019 | 539 |
| 2 | 2021 | 12 | |
| 3 | 2020 | 6 | |
| 4 | 2023 | 5 | |
| 5 | 2016 | 2 |
About Peter Chatfield
Peter Chatfield is a scholar working on Reproductive Medicine, Pulmonary and Respiratory Medicine, Oncology, Radiology, Nuclear Medicine and Imaging and Nuclear Energy and Engineering, having authored 5 papers that have together received 564 indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (3 papers), Ovarian cancer diagnosis and treatment (2 papers), Prostate Cancer Diagnosis and Treatment (2 papers), PARP inhibition in cancer therapy (1 paper), Medical Imaging Techniques and Applications (1 paper) and Bone health and treatments (1 paper). The work is most often cited by research in Oncology (281 citations), Pulmonary and Respiratory Medicine (243 citations), Cancer Research (54 citations), Genetics (89 citations) and Radiology, Nuclear Medicine and Imaging (19 citations). Peter Chatfield has collaborated with scholars based in United Kingdom, New Zealand and Brazil. Frequent co-authors include Dow‐Mu Koh, John Nicholas Staffurth, Emma Hall, Anwar R. Padhani, Holly Tovey, Nina Tunariu, Sophie L. Perry, Chris C. Parker, Roberto Alonzi and Matthew Blackledge. Their work appears in journals such as The Lancet Oncology, Therapeutic Advances in Medical Oncology, Annals of Oncology, Clinical Genitourinary Cancer and JNCI Cancer Spectrum.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.